A Phase I, Single Centre, Randomised, Single Blind, Placebo-Controlled Study to Investigate the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of Inhaled AZD8871 in Healthy Male Japanese Subjects.
Phase of Trial: Phase I
Latest Information Update: 23 May 2018
At a glance
- Drugs AZD 8871 (Primary)
- Indications Asthma; Chronic obstructive pulmonary disease
- Focus Adverse reactions
- Sponsors AstraZeneca
- 23 May 2018 Results presented at the 114th International Conference of the American Thoracic Society
- 24 Oct 2017 Status changed from active, no longer recruiting to completed.
- 22 Sep 2017 Planned End Date changed from 10 Oct 2017 to 4 Oct 2017.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History